Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Takeda
• Treatments: Azilsartan medoxomil; Candesartan; Candesartan cilexetil

Criteria

Inclusion Criteria:

• Has mild to moderate uncomplicated essential hypertension.

• Has a sitting diastolic blood pressure between 95 and <110 mmHg and sitting systolic blood pressure between 150 and <180 mmHg at placebo run-in period (Week -2) or randomization visit.

Exclusion Criteria:

• Has a cardiovascular disease or symptoms

• Has been treated with more than 3 different antihypertensives within 27 days prior to placebo run-in period.

• Has a significant hepatic disorder, hyperkalemia, malignant tumor or significant renal impairment.